Novartis' brand-new gene therapy player AveXis will build $55M plant, hire 200

Novartis
Novartis' headquarters (Novartis)

AveXis, the gene therapy biotech Novartis snapped up for $8.7 billion, will build a new manufacturing plant to produce its specialized therapies.

On-Demand Webinar

De-Risking the Solid Form Landscape of an API

This presentation will discuss how predictable stability and solubility can minimize development timelines and cost. Attend to hear about two case studies exemplifying the importance of understanding the hydration space of an API and how hydrate formation may be avoided by development of a robust crystallization procedure.

The company will build its $55 million plant in Durham, North Carolina, officials announced Tuesday. The company, which expects to employ about 200 at the plant, will get up to $3 million in incentives from the state.

“Our primary focus is to bring gene therapies to patients suffering from devastating rare neurological diseases—such as SMA, genetic amyotrophic lateral sclerosis and Rett syndrome—and continued investment in establishing our manufacturing infrastructure is a critical component to accomplishing this goal,” Andrew Knudten, AveXis chief technical officer, said in a statement.

AVXS-101, the initial gene therapy candidate from the Bannockburn, Illinois-based biotech, is targeted at spinal muscular atrophy, or SMA, Type 1, which is the leading genetic cause of infant mortality.

RELATED: Novartis inks $8.7B AveXis buyout to build gene therapy unit

The new plant compliments AveXis’ “existing state-of-the art manufacturing site in the Chicagoland area,” Knudten said. Bannockburn is about 30 miles from Chicago.

According to a spokesperson, the 170,000-square-foot facility in Durham will primarily produce drug substance, while the 50,000-square-foot plant in Illinois is expected to produce both clinical and commercial product. Construction on the new facility is slated to begin in the second half of this year and be completed in the second half of 2020.

RELATED: Manufacturing costs loom large for personalized CAR-T cancer meds and their need for speed

Analysts said the $8.7 billion deal showed that Novartis’ new CEO, Vas Narasimhan, is prepared to make hefty bets to be a lead player in emerging therapies, which come with specialized manufacturing methods. The AveXis takeover gives Novartis an AAV9 gene therapy manufacturing operation, R&D capabilities and pipeline of prospects to support its ambition to claim a sizable slice of the sector.

Novartis was already the first company to win an FDA nod for a CAR-T therapy with the approval in August of Kymriah. The one-time treatment, which is priced at $475,000, is made from a patient’s own T cells, which are collected and then re-engineered at specialized manufacturing facilities, and then infused back into the patient to attack cancer.

Suggested Articles

AbbVie and Allergan were already jumping through hoops for their merger before a new tax added hundreds of millions to the cost.

Avastin and Herceptin saw U.S. slowdown that's “not very pronounced” after bioisim launched, but Roche execs still warn of "a significant impact.…

Novo Nordisk, which recently completed a wastewater treatment plant for its massive U.S. API site, has made a gift of the $40 million facility.